slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 34,861-34,890
Pages 1,935
Rows per page 30
Slide function
34,861-34,890 of 58,039
32
The slide displays a grid of heatmaps/data tables for different medical categories, with a specific example for NAFLD at the bottom.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
34
The heatmap shows log(OR) values for three TSLP GWAS signals across various conditions.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
43
The chart shows a scatter plot with a regression line indicating a correlation coefficient (rho) of 0.86.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
44
Data shows 23ME '610 consistently outperforms isotype control and anti-PD1 in IFNy production across most tested cancer types.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
51
23andMe | Investor Presentation Deck | 57 slides23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
52
Fiscal year ends March 31.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
53
Includes a callout highlighting the growth in Therapeutics R&D investment.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
54
Balances may not add up due to rounding.23andMe | Investor Presentation Deck | 57 slides · 23andMe
Pitch deck Investor relations 1 hit
05
The table uses a waterfall-style logic to explain the variance between two periods.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
06
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
08
The slide uses a split layout with text commentary on the left and key performance metrics overlaid on an industrial image on the right.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations 1 hit
09
Includes specific segment performance metrics and qualitative drivers for Q1 2023.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations 1 hit
10
Includes specific mentions of Russia exit impact and post-COVID demand normalization.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations 1 hit
16
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
17
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
18
The table includes a footnote clarifying the adjusted basis for specific segments.3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
19
3M | Results Presentation Deck | 20 slides3M | Results Presentation Deck | 20 slides · 3M
Conference presentation Investor relations Beat · Action1 hit
19
The slide uses a heatmap to visualize individual patient outcomes, highlighting clinical improvement vs. worsening.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
20
Clinical trial safety data comparing Pegzilarginase to Placebo.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
26
The chart shows a clear dose-response relationship where the 10.0 mg/kg dose achieves a more significant and sustained reduction in tHcy compared to the 1.0 mg/kg dose.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
27
The slide uses two distinct chart types (Kaplan-Meier survival curve and a time-series pharmacodynamic plot) to support the clinical hypothesis.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
29
Data presented includes age, sex, and region for a total N=32.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
30
The table displays mean/SD and median/range for Plasma Arginine, GMFM-E, and 2MWT, and counts/percentages for GMFCS levels.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
Includes footnotes regarding non-GAAP reconciliation and royalty revenue impacts from Janssen license agreement.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
06
Includes a highlighted column for Q1'23 and detailed footnotes regarding product licensing and arbitration.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
07
The slide includes a disclaimer regarding the date of the expectations and a note about non-GAAP reconciliation.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
09
The chart illustrates the revenue contribution of four products: VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
10
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
11
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit
12
Alkermes | Results Presentation Deck | 21 slidesAlkermes | Results Presentation Deck | 21 slides · Alkermes
Conference presentation Investor relations Beat · Need1 hit